title: Development and characterization of ouabain-resistant human fusion partners.
abstract: The ouabain-resistant mutant cell lines, HOA-1 and HOA-20 were developed from WI-L2-729-HF2 by cloning with increasing concentration of ouabain. Both parent and mutant cell lines were resistant to base analogues, 6-thioguanine (6-TG) and 8-azaguanine (8-AG) to the level of 20 micrograms/ml in the culture medium. The parent cell line WI-L2-729-HF2 was highly sensitive to ouabain, whereas HOA-1 and HOA-20 were resistant to ouabain to the level of 1 microM and 20 microM, respectively. However, all the cell lines were sensitive to HAT-selective medium which is essential for hybrid selection after fusion. All three lymphoblastoid cell lines were positive for Epstein-Barr virus nuclear antigen (EBNA), secreted TNF-beta (lymphotoxin) without any external stimulation, secreted trace amounts of IgG(kappa), which was also present in their cytoplasm and had IgM(kappa) as surface bound immunoglobulin. They also expressed the CD20, CD71 (transferrin receptor) as surface antigens. In addition to these antigens, HOA-20 also expressed CD38 antigen. The karyotype analysis of these cell lines revealed modal chromosomal numbers ranging from 40 to 47. The HLA-A, -B and -C antigens expressed by WI-L2-729-HF2 and its mutants HOA-1 and HOA-20 were identical. Both the HOA-1 and HOA-20 mutants were found suitable for the generation of hybrids after fusion with EBV-transformed human B-lymphocytes.
authors.affiliation: Department of Immunology, Faculty of Medicine, University of Manitoba, Winnipeg, Canada.
authors.forename: R N
authors.initials: RN
authors.lastname: Ramachandra
authors.forename: I
authors.initials: I
authors.lastname: Berczi
authors.forename: E S
authors.initials: ES
authors.lastname: Rector
authors.forename: A H
authors.initials: AH
authors.lastname: Sehon
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology; D000954:Antigens, Surface / Q000276:immunology; D000956:Antigens, Viral / Q000276:immunology; D001375:Azaguanine / Q000494:pharmacology; D002459:Cell Fusion / Q000276:immunology; D002461:Cell Line, Transformed / Q000187:drug effects*; D004351:Drug Resistance / Q000276:immunology; D019309:Epstein-Barr Virus Nuclear Antigens; D004854:Herpesvirus 4, Human / Q000276:immunology; D006650:Histocompatibility Testing; D006801:Humans; D006825:Hybridomas / Q000276:immunology*; D007074:Immunoglobulin G / Q000276:immunology; D007621:Karyotyping; D008050:Lipid A / Q000276:immunology; D008070:Lipopolysaccharides / Q000276:immunology; D008233:Lymphotoxin-alpha / Q000276:immunology; D010042:Ouabain / Q000494:pharmacology*; D013866:Thioguanine / Q000494:pharmacology; D014407:Tumor Cells, Cultured
chemical_list: D000911:Antibodies, Monoclonal; D000954:Antigens, Surface; D000956:Antigens, Viral; D019309:Epstein-Barr Virus Nuclear Antigens; D007074:Immunoglobulin G; D008050:Lipid A; D008070:Lipopolysaccharides; D008233:Lymphotoxin-alpha; D010042:Ouabain; D013866:Thioguanine; D001375:Azaguanine